Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
De Leeneer K, Coene I, Crombez B, Simkens J, Van den Broecke R, Bols A, Stragier B, Vanhoutte I, De Paepe A, Poppe B, Claes K. De Leeneer K, et al. Among authors: bols a. Breast Cancer Res Treat. 2012 Feb;132(1):87-95. doi: 10.1007/s10549-011-1544-9. Epub 2011 May 7. Breast Cancer Res Treat. 2012. PMID: 21553119
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, De Greve J, Fontaine C, Van Den Weyngaert D, Becquart D, Borms M, Cocquyt V, Van Den Broecke R, Selleslags J, Awada A, Dirix L, Van Dam P, Azerad MA, Vandenhoven G, Christiaens MR, Vergote I. Neven P, et al. Among authors: bols a. Breast Cancer Res Treat. 2008 May;109(1):59-65. doi: 10.1007/s10549-007-9628-2. Epub 2007 Jun 26. Breast Cancer Res Treat. 2008. PMID: 17592772 Free article. Clinical Trial.
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY. De Laere B, et al. Among authors: bols a. Clin Cancer Res. 2019 Mar 15;25(6):1766-1773. doi: 10.1158/1078-0432.CCR-18-1943. Epub 2018 Sep 12. Clin Cancer Res. 2019. PMID: 30209161 Free PMC article. Clinical Trial.
Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: A real standard?
Veereman G, Vlayen J, Robays J, Fairon N, Stordeur S, Rolfo C, Bielen D, Bols A, Demetter P, D'hoore A, Haustermans K, Hendlisz A, Lemmers A, Leonard D, Penninckx F, Van Cutsem E, Peeters M. Veereman G, et al. Among authors: bols a. Crit Rev Oncol Hematol. 2017 Jun;114:43-52. doi: 10.1016/j.critrevonc.2017.03.008. Epub 2017 Apr 1. Crit Rev Oncol Hematol. 2017. PMID: 28477746 Review.
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L. De Laere B, et al. Among authors: bols a. Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12. Prostate. 2018. PMID: 29431193
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T. Almhanna K, et al. Among authors: bols a. Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19. Invest New Drugs. 2017. PMID: 28527133 Clinical Trial.
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, De Maeseneer D, Strijbos M, Bols A, Fransis K, Oeyen S, van Dam PJ, Van den Eynden G, Rutten A, Aly M, Nordström T, Van Laere S, Rantalainen M, Rajan P, Egevad L, Ullén A, Yachnin J, Dirix L, Grönberg H, Lindberg J. Mayrhofer M, et al. Among authors: bols a. Genome Med. 2018 Nov 21;10(1):85. doi: 10.1186/s13073-018-0595-5. Genome Med. 2018. PMID: 30458854 Free PMC article.
19 results